Remove Medicare Remove Peripheral Arterial Disease Remove Stents
article thumbnail

SCAI Scientific Sessions 2025 to Feature Presentations on TAVR, PAD and PE 

DAIC

Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)

TAVR 52
article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.

article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronary arteries.4 2,3 It has shown 99.6%

article thumbnail

Outpatient vascular care : Good, bad or ugly?

Dr. Anish Koka

Most have gotten used to egregiously bad coverage of current events that fills the pages of today’s New York Times, but even by their now very low standards a recent telling of a story about peripheral artery disease was very bad. These payments made him one of the highest paid vascular surgeons in the country.